A global specialty pharmaceutical company focused on chronic endocrine diseases
Dedicated to bringing high quality products to the global endocrine market
Focused on addressing the major unmet clinical and patient needs for patients with chronic endocrine diseases
Innovative research activities focused on circadian-based endocrinology
Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.
The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.
To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.
On track to becoming a world leading specialty pharma company in endocrinology
Infrastructure and supply chain now in place to provide Infacort® and Chronocort® as unlicensed medicines to patients on a Named Patient basis
The agreement covers the commercialisation in Israel of Diurnal’s novel therapies for adrenal insufficiency, Infacort® and Chronocort®.